Shailendra Kumar Yadav et al /J. Pharm. Sci. & Res. Vol. 12(8), 2020, 1029-1039

ISSN:0975-1459
Journal of Pharmaceutical Sciences and Research
www.jpsr.pharmainfo.in

A Review on Depression and Anti-Depressant Activity of Various Medicinal Plants

Shailendra Kumar Yadav, Rahul Srivastava, Dharamveer
Department of Pharmacology, Hygia Institute of Pharmaceutical Education and Research.

Abstract:

Depression refers to a large rang of psychological state issues defined by the absence of a positive effect (a loss of interest and enjoyment in ordinary things and experiences), low mood and a variety of associated emotional, cognitive, physical and activity symptoms. Identifying the mood changes between clinically vital degrees of depression (for example, major depression) and people occurring 'normally' remains problematic and it's best to contemplate the symptoms of depression. The identification of major depression relies not solely on its severity however additionally on persistence, the presence of alternative symptoms, and therefore the degree of useful and social impairment.

However, there seems to be no strict 'cut-off' between 'clinically significant' and 'normal' degrees of depression; the bigger the severity of depression, the bigger the morbidity and adverse consequences. Once taken in conjunction with alternative aspects that require to be thought of, like length, stage of health problem and treatment history, there are a unit appreciable issues once making commonly, mood and effect of exceedingly major depressive health problem area unit unreactive to circumstance, remaining low throughout the course of every day, though for a few individuals mood varies diurnally with gradual improvement throughout the day solely to come back to a low mood on waking. For others, a person's mood is also reactive to positive experiences and events, though these elevations in mood don't seem to be sustained, with depressive feelings re-emerging, typically quickly.

Keyword: Depression, neurotransmitters, stress, anti-depressants.

INTRODUCTION:

Definition: "A psychological state disorder characterised by persistently depressed mood or loss of interest in activities, inflicting vital impairment in lifestyle. Depression is that the common mental disorder that presents with depressed mood, loss of interest or pleasure, feeling of guilt. Depression will result in suicide."

"Depression may be a state of psychological state. It's characterised by deep, long lasting feelings of unhappiness or despair. Depression will modification an individual's thinking/feelings and additionally affects his/her social behaviour and sense of physical well-being. It will have an effect on individuals of any age group together with young kids and youths. It will run in families and typically starts between the ages of fifteen and thirty years."[1]

As calculable by WHO, depression shall become the second largest sickness in terms of morbidity by another decade within the world, already one out of each 5 ladies and not simply adults, however 2 % of college kids, and 5 % of teenagers conjointly suffer from depression and these largely go unidentified. Depression has been the most typical reason why folks return to a shrink, though the common man's perception is that each one psychological issues are depression. What one sees in most patients is that the story associated with depression. Folks still believe that it's due to some weakness in temperament, or that one will cure it by oneself, or that medication would go womb-to-tomb and are mere sedatives. Of these are myths, and largely created by religion healers, or unqualified counsellors, and non-medical specialists for his or her own unconditional interest and mostly by an unaware of society. An inflated awareness and approach to psychiatrists has been the most reason for the rise in range of patients and not essentially a rise in prevalence. With newer medication, and higher facilities, treating depression has become easier and the general public responds alright to treatment and come back to optimum functioning terribly presently.

Types of depression: Depressive sickness comes in numerous forms, even as several different illnesses:

- **Major depression** is manifested by a combination of symptoms that interfere with ability to work, sleep, eat and luxuriate in once pleasant activities. These disabling episodes of depression will occur once, double or many times in a very time period.
- **Dysthymia**, a less severe kind of depression involves long, chronic symptoms that don't disable, however keep you from working at "full steam" or from feeling sensible. Generally folks with Dysthymic depression conjointly expertise major depressive episodes.
- **Manic-depressive** or bipolar isn't nearly as current as different varieties of depressive sicknesses. It involves cycles of depression and elation or mania. Generally the mood switches are dramatic and speedy, however most frequently they're gradual.

Once within the depressed cycle, one will have any or all different the symptoms of a depressive sickness. Once within the wild cycle, any or all symptoms listed beneath mania could also be fully fledged. Mania typically affects thinking, judgment, and social behaviour in ways in which could cause serious issues and embarrassment. [1]

PATHOPHISIOLOGY OF DEPRESSION:

Biochemical basis of depression:

The enormous progress within the field of neurobiology within the twentieth century brought U.S. fascinating insights into the character of mental processes. Beginning with anatomy and electrophysiology at the start of the twentieth century, neurobiology now is a knowledge domain field occupying several areas of biological investigations, starting from molecular studies of cell and factor operate to brain-imaging techniques, therefore

broadening our information of the cellular and molecular machinery that regulates behaviour. Carlsson and a number of other Nobel prize winners has considerably contributed to the understanding of brain function, and investigations of medical specialty disorders are currently absolutely based mostly in basic neurobiology.

Synaptic Transmission:

One of the foremost necessary advances in neurobiology was the pioneering work of Otto Loewi and alternative scientists, i.e., that chemical transmission is the major means that by nerves communicate with each other. It is documented that the pre- and postsynaptic events are extremely regulated and are the premise for malleability and learning inside the central nervous system (CNS). Chemical transmission needs many steps as well as synthesis of the neurotransmitters, their storage in liquid body substance vesicles and their regulated unleash into the colligation cleft between pre- and postsynaptic neurones however conjointly the termination of neurochemical action and therefore the induction of the ultimate cellular responses via completely different steps within the signal transduction cascade.

Figure 1 is a schematic illustration of a colligation for classic neurotransmitters. The initial step of synthesis is that the expedited transport of amino acids from blood to the brain, wherever precursors are regenerate via catalyst reactions into transmitters that are stored in synaptic vesicles and eventually free into the synaptic cleft by a Ca2+-dependent method. The speed of neurochemical unleash relies on the firing rate of the neurones which suggests that conditions or medication that alter the firing rate modify the discharge of the transmitter. An additional necessary restrictive mechanism of unleash involves the somatodendritic autoreceptors since binding of the free transmitter molecules results in reduced synthesis or additional unleash from the presynapse. The synaptic effects are terminated by binding of the transmitters to specific transporter proteins and uptake into the presynapse wherever they're metabolized by enzymes as an example, enzyme (MAO), or hold on once more within the vesicles.



Fig1:Schematic illustration of a synapse and the steps of chemical transmission. Precursors area unit transported from blood into the brain (A), regenerate into transmitters via accelerator processes, and keep in junction vesicles (B). The transmitter's area unit discharged into the junction cleft (C), wherever they either react with presynaptic auto receptors to control synthesis and unharnessed, or with postsynaptic receptors to induce the events of the downstream signal transduction cascade (D). MAO, monoamine oxidase.

Neurotransmitter molecules don't cross the postsynaptic membrane, however induce a cascade of reactions via their initial binding to surface receptors at intervals the post-synaptic membrane that area unit typically coupled to G nucleotide-binding proteins (G-proteins). These G-proteins represent essential initial restrictive elements in transmembrane communication as a result of the modulate variety of effectors systems at intervals the cells, together with adenylylcyclases, phospholipases, and therefore the phosphoinositidemediated system. The first cellular events of the signal transduction cascade (i.e., increase in concentrations of intracellular metallic element ions or second messengers, like cyclic nucleotide fcAMP) initiate a pathway via phosphorylation of macromolecule kinases that successively regulates several biological responses and controls short- and semi permanent brain functions by regulation of somatic cell particle channels, receptor modulation, neurochemical unharnessed and ultimately, synaptic potentiation and neuronal survival. Disrupted function in one or more steps of this chemical transmission may be a crucial mechanism underlying depression. On the other hand, it is now well established that these mechanisms are targets of antidepressant action.

Monoamine hypothesis:

The first major hypothesis of depression was developed concerning thirty years ago and planned that the most symptoms of depression are due to a purposeful deficiency of the brain monoaminergic transmitters vasoconstrictive (NE), 5-HT, and/or Intropin (DA), whereas mania is caused by purposeful more than monoamines at important synapses within the brain. Proof for this hypothesis came from clinical observations and animal experiments that showed that the medicament antihypertensive which causes a depletion of presynaptic stores of NE, 5-HT, and DA, elicited a syndrome resembling depression. In distinction to the consequences obtained with antihypertensive high spirits and active behavior were ascertained in some patients being treated with iproniazid, a compound synthesized for the treatment of infectious disease that exaggerated brain concentrations of NE and 5-HT by inhibiting the metabolic protein MAO.

Considering the origin of the noradrenergic, serotonergic, and dopaminergic neurons within the brain and their projections into several areas of the brain, it's clear that monoaminergic systems are accountable for several activity symptoms, like mood, vigilance, motivation, fatigue, and body process agitation or retardation. Abnormal function and therefore the activity consequences of either depression or the wild state could arise from altered synthesis, storage or unleash of the neurotransmitters additionally disturbed sensitivity of their receptors or sub cellular traveler functions.

Neurotransmitter concentration:

Many makes attempt are created to prove the hypothesis of reduced aminoalkane accessibility by measure of neurotransmitters and/or their metabolites in postmortem brain tissues and body fluids, like body fluid (CSF), blood, and urine. Though perennial knowledge showing small levels of the NE substance a-methoxy-4-hydroxyphenylglycol (MHPG) that indicates NE.

Turnover in brain, support the hypothesis of a deficient noradrenergic system, the results are inconsistent. Equally to the noradrenergic system, the information on determinations of 5-HT and its substance 5-hydroxyindoleacetic acid (5-HIAA) couldn't prove the hypothesis of solely reduced serotonergic transmission. Several studies reportable small central serotonergic turnover in major depression; however findings additionally urged that reduced 5-HT.

Function might not be present in all depressed patients. These discrepancies between studies could mirror each method issues like difficulties in measurement the amines once varied postmortem delays and therefore the incontrovertible fact that determinations of neurotransmitters or their metabolites in CSF or blood, events in many brain areas and not in restricted nuclei.

Similarly to the info on neurochemical concentrations, the results on the chance of impaired activity of the enzymes for synthesis and degradation of monoamines aren't convincing. Amino acid hydroxylase and essential amino acid hydroxylase are essential for NE and 5-HT synthesis, severally were found to be up- or down regulated in postmortem brain samples, suggesting a minor importance for transmitter synthesis. Similarly, no conclusive abnormalities were found within the degrading activity of MAO.

The paradigm of aminoalkane depletion that links clinical state to aminoalkane deficiency, nicely offers the chance of investigation the result of aminoalkane concentration on behavior and provides Us abundant extra info on its impact on the psychopathology of depression. Addition of α-methylparatyrosine that inhibits the NE-synthesizing protein amino acid hydroxylase, results in a depletion of NE within the junction. An identical influence on the metabolism of 5-HT is obtained by application of a tryptophan-free aminoalkanoic acid mixture that induces a speedy cerebral depletion of essential amino acid and ultimately a decrease in 5-HT concentrations. Apparently, depletion of monoamines didn't induce or worsen the symptoms of depression in healthy controls or unmedicated patients which implies that aminoalkane deficiency alone isn't decent for the clinical syndrome. However in patients presently receiving drug treatment, the medicament response was transiently reversed in a manner that was passionate about the category of medicament. These results support the proof that associate in antidepressants need an intact aminoalkane system for therapeutic action, however the pathophysiology of depression might not be explained by one monoamine-related mechanism.

Transporters for neurochemical reuptake:

Transport proteins play an important role in monoaminergic transmission: they scale back the provision of neurotransmitters within the junction cleft and therefore terminate the result of the neurotransmitters on pre- and postsynaptic receptors. Though abundant of our information regarding transporter dysfunction comes from animal and postmortem brain studies, the 5-HT transport system isn't restricted to tissues of the central nervous system however it is additional gift in human platelets. This provides us the chance to analyze it's performing in vivo and in numerous states of depression. Completely different substances are accustomed mark the super molecule and different investigations measured the active uptake of 5-HT and a minimum of for platelets. There's currently agreement a couple of decreased transporter function in major depression- A finding that wasn't ascertained in different medicine disorders. In distinction, the results with postmortem samples aren't as convincing as those with platelets; probably because of inconsistencies within the choice of subjects or the abundant mentioned issues of investigation the quickly degrading proteins once varied postmortem delays.

The problems of postmortem investigations could also be overcome by practical imaging techniques that enable a noninvasive investigation of the 5-HT transporter within the human brain. Exploitation the tactic of single photon emission computed tomography (SPECT) and also the radio labeled tracer I-β-CIT ([123 I]-2β-carbomethoxy-3β-(4iodophcnyl) tropane), the decrease in 5-HT transport that had already been known in platelets was confirmed for the system. Moreover, there may even be a genetic basis for this dysfunctional 5-HT transport since a standard polymorphism inside the promoter region of the 5-HT transporter cistron ends up in altered transcriptional activity and thence to diminished expression of the cistron. Curiously, this polymorphism for "lower function" was found a lot of times in depressed patients.

As regards the NE transporter, few studies are conducted to live the NE uptake sites. While not a perfect peripheral model, most experiments were applied in postmortem samples and also the few results are polemical. There was additionally no relationship to genetic variants of the NF: transporter.

Neurotransmitter receptors:

In addition to aminoalkane deficiency, associate abnormality in transmission may also arise from changes in receptor function which suggests either changes in coupling between transmitters and receptors or changes within the downstream signal transduction cascade. For each the noradrenergic and serotonergic systems, a multiplicity of receptors are known to this point, every classified in line with its pharmacologic or molecular characteristics. NE transmission is regulated via α- or β-adrenoccptors and their varied subtypes with an equivalent pharmacological property in brain and periphery. Receptor classification for the serotonergic system has proceeded rapidly and so far we all know of many major classes, starting from 5-HT1 to 5-HT7 receptors, every with additional subtypes.

Receptors aren't static entities: their numbers and affinities are regulated by several factors for instance, the transmitter concentration, that ends up in antagonistic down- or up regulation within the receptor macromolecule. Despite intensive investigation over the years, our data of alterations in aminoalkane receptor numbers or affinities in untreated depressed patients is comparatively poor and unconvincing. The of times reportable super sensitivity of presynaptic α2 -adrenoceptors that modulate the discharge of NE,

additionally altered numbers and affinities of 5-HT1 and 5-HT2 receptors in brain and/or platelets are the topic of a lot of discussion.

Due to the fast development of biology, interest has shifted from the mere determination of the receptor numbers or affinities toward the signal transduction cascade. There's mounting proof for the role of those mechanisms within the modulation of somatic cell activity and pathophysiology of mental disorders using this new approach, many studies in peripheral cell model systems and/or in postmortem brain tissue report alterations in G-proteins, at multiple sites of the cAMP pathway, and in macromolecule kinases. These findings have semiconductor diode to the formulation of a molecular and cellular hypothesis of depression that proposes that signal transduction pathways are in a pivotal position in the CNS, in that they affect the functional balance between multiple neurotransmitter systems and physiological processes. [2]

EPIDEMIOLOGY:

Prevalence:

The 12-month prevalence of major depressive disorder varies considerably across countries but is approximately 6%, overall. The lifetime risk of depression is three times higher (15–18%), meaning major depressive disorder is common with almost one in five people experiencing one episode at some point in their lifetime. Hence, in primary care, one in ten patients, on average, presents with depressive symptoms, although the prevalence of depression increases in secondary care settings. Notably, the 12-month prevalence of major depressive disorder is similar when comparing high-income countries (5·5%) with low-income and middle-income countries (5·9%), indicating that major depressive disorder is neither a simple consequence of modern day lifestyle in developed countries, nor poverty. Furthermore, although social and cultural factors such as socioeconomic status can have a role in major depression, genomic and other underlying biological factors ultimately drive the occurrence of this condition. The most probable period for the onset of the first episode of major depression extends from midadolescence to mid-40s, but almost 40% experience their first episode of depression before age 20 years with an average age of onset in the mid-20s (median 25 years). Across the lifespan, depression is almost twice as common in women than in men and in both genders, a peak in prevalence occurs in the second and third decades of life with a subsequent more modest peak in the fifth and sixth decades. The difference in prevalence of depression between men and women is referred to as the gender gap in depression and is thought to be linked to sex differences in susceptibility (biological and psychological), and environmental factors that operate on both the micro level and macro level.

Course and prognosis:

The onset of depression is usually gradual but it can be abrupt sometimes and depression's course throughout life varies considerably. For most patients, the course of illness is episodic and they feel well between acute depressive episodes. However, the illness is inherently unpredictable and therefore the duration of episodes, the number of episodes over a lifetime and the patterns in which they occur are variable. Major depressive disorder is a recurrent lifelong illness and so recovery is somewhat of a misnomer. In practice, the term is used to describe patients that are no longer symptomatic and have regained their usual function following an episode of major depression. With treatment, episodes last about 3–6 months and most patients recover within 12 months. Long-term stable recovery is more probable in community settings and among those patients seen by general physicians than in hospital settings. Longer-term (2–6 years), the proportion of people who recover is much less, dropping to approximately 60% at 2 years, 40% at 4 years, and 30% at 6 years with co morbid anxiety having a key role in limiting recovery. The likelihood of recurrence is high, the risk increases with every episode and overall almost 80% of patients experience at least one further episode in their lifetime. The probability of recurrence increases with each episode and the outcome is less favorable with older age of onset. Furthermore, although more than half of those affected by a major depressive episode recover within 6 months and nearly three-quarters within a year, a substantial proportion (up to 27%) of patients do not recover and go on to develop a chronic depressive illness, depending upon baseline patient characteristics and the setting within which they are managed.

A number of the world population suffers from depression and anxiety at some time during their life, and these conditions are the most prevalent psychiatric disorders known. About 450 million people suffer from a mental or behavioral disorder but only a small minority of them receives even the most basic treatment (WHO, 2001). This amounts to 12.3% of the global burden of disease which may rise to about 15% by 2020. With this alarming anticipated rise, World Health Organization envisaged that depression will become the second leading cause of premature death or disability worldwide by the year 2020 (WHO, 2001). Approximately two-thirds of the anxious or depressed patients respond to the currently available treatments but the extent of improvement is still disappointing, coupled with the various physiological side effects and tolerance on chronic treatment. [4]

DIAGNOSIS:

Patient presentations can be complex. For this reason, many clinicians develop clinical case formulations. Clinical case formulations are case maps which categorize and organize clinical variables such as depressive symptoms, aggressive behaviors and maintaining or reinforcing factors. One model of clinical case formulation is the clinical pathogenic map (CPM). The CPM organizes clinical variables and identifies the multiple relationships between clinical variables such that treatment may be targeted to produce the highest impact. A comprehensive evaluation is required to develop an accurate CPM. Establishing an accurate and global clinical formulation is essential to develop treatment plans that meet patients' unique needs. This may increase the probability of

treatment success by matching effective treatment models with the clinical problems they are designed to address. For the purposes of this article, clinical examinations are divided into three parts. These three parts are mental status examination and presentation, comprehensive history and structured clinical interview with additional diagnostic measures. Mental status identifies key clinical constructs such as speech, motor activity, hygiene and cognitive processes etc. This can be accomplished using standardized tools such as the Mini-Mental State Examination (MMSE).

The MMSE asks the patient to address various constructs of cognitive functioning such as orientation (time and place), immediate and delayed verbal recall and attention. A score below 26 generally indicates cognitive impairment. Other features of mental status and presentation can be identified through behavioral observation. Identifying mental status provides a context for understanding patient functioning. A complete history includes, but is not limited to family structure, early childhood development, education, prior criminal activity, past clinical and physical health problems, social and occupational history, relationship status and prior neurological insult or event (e.g., TBI or stroke). A comprehensive examination provides context to a case conceptualization and identifies if there is a personal or family history of psychological health problems or preexisting risk factors which may be relevant to current psychological status. Clinicians may use semistructured clinical interviews such as the Structured Clinical Interview for DSM-IV (SCID) or the diagnostic interview schedule (DIS). These interviews provide questions, which relate to DSM-IV Axis me (psychological health disorders) and Axis II (personality disorders). The advantage of semi structured interviews is that they are standardized for administration and scoring.

Additionally, measures such as the SCID are well researched and scientifically accepted. Because they comprehensively address disorders identified in the DSM-IV, structured clinical interviews help rule in or rule out co-occurring disorders and can increase the accuracy of diagnostics. The American financier and philanthropist Bernard Baruch said “If all you have is a hammer, everything looks like a nail.” If a clinician believes that a patient is depressed, he/she is likely to find this in unstructured questioning. This strategy may find an existing depression but fail to find other problems. Similarly, it may identify features of depressions which are part of another discrete diagnosis. For example, PTSD and depression have a number of overlapping symptoms (e.g., sleep impairment, psychomotor agitation and clinical distress). Instituting evidence-based care for PTSD (exposure therapy) is unlikely to produce desired effects. Thus, accurate diagnostics are needed to guide prescribed models of care and reduce the risk of implementing proscribed treatments. Thus, a comprehensive evaluation is recommended to limit errors associated with inaccurate or partial diagnosis. A global assessment that captures an array of potential phenomena as opposed to searching for a discrete disorder such as depression (clinical bias) appears likely to facilitate the appropriate treatment modalities. A comprehensive evaluation should provide substantial data to develop an idiographic case conceptualization which identifies a constellation of clinical variables that comprise psychological health problems and maintain clinical distress and disease processes. As described above, comprehensive evaluations inform clinical case conceptualization or clinical pathogenic mapping constructions. [5]

SYMPTOMS:

Psychological symptoms:

Continuous low mood or sadness,
Feeling hopeless and helpless,
Having low self-esteem,
Feeling tearful,
Feeling guilty,
Having self-destructive thoughts or thoughts of harming yourself,

Physical symptoms:

• Moving or speaking additional slowly than usual,
• Changes in craving or weight (usually small, however typically increased),
• Constipation,
• Un-explained aches and pains,
• Lack of energy.

Social symptoms:

• Avoiding contact with friends,
• Taking half in fewer social activities,
• Neglecting your hobbies and interests,
• having difficulties in your home, work or family life.

CAUSES OF ILLNESS –

Environmental factors and factor part

Genetic Causes of Depression Most of the revealed factor tic association studies of mood disorders have centered on practical polymorphisms (DNA sequence variations that alter the expression and/or functioning of the gene product) within the loci coding the monoamine neurotransmitter transporter (SLC6A4), monoamine neurotransmitter 2A receptor (5HTR2A), amino acid hydroxylase (TH) (the limiting protein for monoamine neurotransmitter synthesis), essential amino acid hydroxylase one (TPH1) (serotonin synthesis), and catechol-o-methyltransferase (COMT) (dopamine catabolism) . Its long been legendary that depressive diseases will run in families, however till fairly recently it had been not absolutely legendary whether or not folks transmitted a status to those diseases or if one thing else like the atmosphere was verity offender. A person who analysis depression is able to verify that to some extent depressive diseases is transmitted. What seems to be transmitted may be a vulnerability to depression. This implies that if we've shut relatives United Nations agency have emotional disturbance, we tend to might inherit a bent to develop the health problem. It doesn't mean that we tend to are destined to become depressed. Manic-depressive psychosis incorporates a robust genetic influence. Of these with manic-depressive psychosis, more or less five hundredth of them has a parent with a history

of emotional disturbance. Once a mother or father has manic-depressive psychosis, their kid can have a twenty fifth likelihood of developing some form of emotional disturbance. If each oldster has manic-depressive psychosis, the prospect of their kid conjointly developing manic-depressive psychosis is between five hundredth and seventy fifth. Brothers and sisters of these with manic-depressive psychosis are also eight to eighteen times additional possible to develop manic-depressive psychosis and a pair of to ten times additional likely to develop major depression than others with no such siblings. Twin Studies: abundant of what we all know concerning the genetic influence of emotional disorder relies upon analysis that has been finished identical twins. Identical twins area unit terribly useful to researchers since they each have the precise same ordination. It's been found that once one monozygotic twin becomes depressed the opposite also will develop emotional disorder some seventy six of the time. Once identical twins area unit raised except for one another, they'll each become depressed concerning sixty seven of the time. As a result of each twins become depressed at such a high rate, the implication is that there's a powerful genetic influence. If it happened that once one twin becomes clinically depressed the opposite perpetually develops depression, then emotional disorder would possible be entirely genetic. But as a result of the speed of each identical twin developing depression isn't nearer to 100% this tells America that there are unit alternative things that influence somebody's vulnerability to depression. These might embody environmental factors like childhood experiences, current stressors, traumatic events, exposure to substances, medical sicknesses, etc. analysis has additionally been finished fraternal twins. Not like identical twins that have a similar ordination, these siblings share solely concerning five hundredth of their genetic makeup and don't essentially look alike. Studies have shown that once one dizygotic twin becomes depressed, the opposite additionally develops depression concerning nineteen of the time. This can be still the next rate of depression in comparison to overall rates for the overall public, once more inform towards a genetic influence within the development of emotional disorder.

Environmental Causes of Depression

Environmental causes of depression embody events like stress, traumatic events and childhood difficulties. These area unit events which will happen to anyone and that they happen throughout everyday lives. {They area unit they're} thought-about factors that are outside folks. Some researchers visit these events as social science or psychosocial factors as a result of they're a "meeting" or "combination" of events that happen in society and therefore the function and workings of the human mind. Researchers have renowned for a few time that the experiences (events) we've in our lives will and do have an effect on our psychological state. Thoughts, emotions and behaviors' of individual's area unit influenced by the previous experiences in their lives. These experiences will embody past relationships, childhood development and past crises. The key to development of emotional disorder in some individuals appears to be however they react to the assorted environmental causes or factors in their everyday lives.

Stress:

There seems to be a really advanced relationship between nerve-wracking things the reaction of the individual's mind and body to worry and therefore the development of emotional disorder. Most researchers believe that for a few individuals there's a right away relationship between a nerve-wracking event and therefore the development of depression. What's fascinating to notice is that this stress may be negative or positive. Samples of negative stress area unit loss of a dear, loss of employment, loss of a relationship and divorce. Samples of positive stress area unit coming up with for a marriage, making ready for a brand new job, and moving to a brand new town. Each negative and positive stress from environmental events will precede the event of depression.

Traumatic Events:

It is a proven fact that many of us have old a traumatic event before developing depression. Traumatic events within the lives of individuals embrace loss of a love, a heavy medical malady, the top of a wedding or vital loss. These varieties of events will destroy the sense of management and stability during a person's life, usually resulting in emotional distress.

Childhood Difficulties:

It has long been glorious that individuals with severe difficulties in childhood have higher rates of depressive disorder. The foremost common childhood difficulties embrace sexual, emotional or physical abuse, dysfunctional upbringing, parental separation, and psychological state in one or each of the fogeys. One in every of the foremost tough emotional events for a baby to endure is that the separation or death of a parent before the age of 11. Kids that have old this event conjointly demonstrate the next likelihood of developing depression.

Synthetic Chemicals:

Every day we have a tendency to absorb artificial chemicals from everywhere. From preservatives, additives and hormones that are found and additional to such a large amount of our foods, pesticides that are sprayed and air and pollution further. Studies have shown that air and pollution alone will cause cancer and different diseases. Artificial chemicals and pollutants are currently being additional closely checked out as a link to depression and Major Depressive episodes.

Noise Pollution: Pollution has been coupled to aggression, high blood pressure, inflated stress levels, tinnitus, deafness and disruptions in sleep. Specifically, symptom is coupled to severe depression, panic attacks and forgetfulness. Continual exposure to pollution has conjointly been coupled to disorder and inflated pressure. Someone with potential depressive tendencies can become even additional liable to depression with continual, prolonged exposure to pollution.

Electrical Pollution: A lot of the electrical instrumentality we have a tendency to use works off of radio waves and these radio waves are found to induce depression and rage. The precise causes on why don't seem to be nonetheless

glorious and in contrast to different varieties of environmental causes of depression, electrical pollution can't be seen, heard, tasted, or felt. But it will have a negative impact on our mind and body.

Natural and harmful Disasters: Natural and harmful disasters, like hurricanes, earthquakes, or fires and even manmade disasters like bombings and war will push an already vulnerable person into a severe major Depression. The National Centre for Environmental Health has found that individuals, World Health Organization ordinarily wouldn't be a candidate for depression will become depressed when major life sterilization episodes like their house being destroyed during a natural disaster.

Some Others Cause:

It is caused because of a combination of many factors that include—but isn't restricted to—genetic factors, life events, stress. Some causes are:

- **Psychiatric disorders**: Depression can coexist as a part of undiagnosed psychiatric disorders, such as obsessive-compulsive disorder (OCD), social phobia, schizophrenia. A detailed assessment by a mental health expert is recommended in such cases.
- **Life stressors**: Common life stressors—like problems relating to work, interpersonal relationships, finances can contribute to depression.
- **Physical health problems**: Distress experienced by a person because of a physical illness that is hard to cope with can lead to showing signs of depression. It is important to consult a medical professional in such cases.
- **Other**: Imbalanced neurotransmitters, genetics (hereditary), trauma and high levels of stress, mental illnesses such as schizophrenia, heart disease, cancer and HIV, use of certain medications, alcohol and drug abuse, breakup of a relationship or loss of a loved one.

TREATMENT OF DEPRESSION:

There are multiple treatment options available. The course of treatment is decided based on the severity of the illness and other physiological, cognitive and social factors. In some cases, medication is prescribed. Alternatively, a combination of medication and psychotherapy is employed as a mode of treatment. In addition, the person is also referred to specialists to be treated for coexisting medical conditions like diabetes or thyroid that may have contributed to the depression. Several psychological therapies have been found to be effective in treating depression. A few examples of the types of therapy used are:

Cognitive Behavioural Therapy (CBT): CBT is one of the most commonly used treatment methods for depression. It is a structured, conversation-based therapy that helps identify dysfunctional thought patterns and behaviours. Negative thoughts like "I can't do anything right" are identified and replaced with positive thoughts like "I can do this correctly," leading to more effective and positive behaviour. CBT works based on the fact that a change in a person's behaviour can lead to an improvement in thoughts and mood. This can be something as simple as stepping out of the house and taking a 15-minute walk every day. During therapy, the therapist and client set goals and work towards them.

Interpersonal Therapy (IPT): This is a structured therapy process that focuses on helping the person improve their interpersonal relationships. The therapist teaches the client to evaluate their interactions with others, and become aware of patterns of self-isolation and difficulties faced in getting along with; relating to; or understanding others. IPT is a time-limited treatment with an initial, middle and final stage.

Dialectical behavior therapy (DBT): DBT is a conversation-based approach that focuses on building skills in many areas, such as distress tolerance, mindfulness, emotional regulation. It helps target specific symptoms of depression and teaches skills to manage them. It is found to be very helpful for those that struggle with thoughts of suicide; DBT additionally helps purchasers produce semi permanent goals and work towards it.

Electroconvulsive therapy (ECT): This treatment is employed for severe styles of psychiatrical conditions. Shock treatment is thought as 'shock treatment' in common idiom. Once medication or psychotherapy isn't effective in treating severe symptoms like acute psychopathy or thoughts of suicide, or if someone cannot take antidepressants, then shock treatment is also thought of. This treatment is often combined with antidepressants and psychotherapy for a few people.

Alternative therapies: Whereas speak therapies like CBT are the foremost normally used styles of treatment for depression, there are many different styles of medical care which will be used. Like animal aided medical care (AAT); play medical care; yoga therapy; communicatory arts therapy which incorporates music, movement and drama medical care. These are less a couple of person's ability level, and a lot of concerning them employing an explicit medium as how to form sense of their issues.

Aside from these, another crucial aid within the treatment of depression is psycho education. It involves teaching someone concerning their unwellness, however it is often treated, and the way to acknowledge signs of relapse to induce the treatment they have before a replacement onset of the unwellness. Family psycho education is a vital a part of the person's recovery process. It helps cut back their distress, confusion and anxiety, permitting them to be gift to the wants of their dearest scuffling with depression.

Similarly, help teams, support groups—now turning into a lot of on the market in urban spaces are giving individuals an area to share their experiences and feelings; get info concerning qualified specialists to approach for treatment and therapy; and study useful community resources.

ANTIDEPRESSANTS:

These are medication which might elevate mood in depressive unwellness. Much all antidepressants have an effect on monoaminergic transmission within the brain in a technique or the opposite and plenty of them produce other associated properties. Significantly over the past 20 years, an oversized range of associatetidepressants with an assortment of effects on reuptake/ metabolism of biogenic amines and on pre/postjunctional aminergic/ cholinergic

receptors became on the market so a cogent classification is troublesome. The subsequent operating classification is also adopted.

CLASSIFICATION OF ANTI-DEPRESSANTS

I. Reversible inhibitors of MAO-A (RIMAs)
Moclobemide, Clorgyline

II. tricyclic antidepressant drug antidepressants (TCAs)

• A NA 11 + 5-HT uptake inhibitors, Imipramine, amitriptyline, tricyclic antidepressant, Doxepin, Dothiepin
• B. preponderantly an uptake inhibitors
Desipramine, nortriptyline, Amoxapine, Reboxetine

III. Selective serotonin uptake inhibitors (SSRis)
Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Escitalopram

IV. Atypical antidepressants
Trazodone, Mianserin, Mirtazapine, Venlafaxine, Duloxetine, Tianeptine, Amineptine, Bupropion several alternative medications like protriptyline, Maprotiline, Nafazodone are marketed in alternative countries.

Table 1: Description of plants having antidepressant activity

S. NO.	PLANT NAME	COMMON NAME	FAMILY	PART USED
1.	*Areca catechu*[16]	Betel nut	Arecaceae	Areca nut
2.	*Apocynum venetum* Linn.[17]	European dogbane	Apocynacea	Leaves
3.	*Albizzia julibrissin* [18]	Persian silk tree	Fabaceae	Bark
4.	*Albizzia lebbeck* [19]	Siris tree	Mimosaceae	Bark
5.	*Aniba riparia* [20]	St. John's wort	Lauraceae	Unripe fruit
6.	*Aloysia polystachya* [21]	Tede burro	Verbenceae	Aerial part
7.	*Allium cepa* [22]	Bulb onion	Liliaceae	Bulb powder
8.	*Asparagus racemosus* [23]	Shatavari	Liliaceae	Root
9.	*Bacopa monniera* [24]	Brahmi	Scrophulariaceae	Aerial part
10.	*Boophone distica* [25]	Tumbleweed	Amaryllidaceae	Whole plant
11.	*Bupleurum falcatum*[26]	Chinese thoroughwax	Apiaceae	Fruit
12.	*Clitoria ternatea* [27]	Butterfly-pea	Fabaceae	Plant powder
13.	*Canavalia brasiliensis* [28]	Brazilian jackbean	Fabaceae	Seed
14.	*Curcuma longa* [29]	Turmeric	Zingiberaceae	Root (rhizome)
15.	*Cecropia glazioui* [30]	Embauba	Cecropiaceae	Leaves
16.	*Cimicifuga racemosa* [31]	Black snakeroot	Ranunculaceae	Root (rhizome)
17.	*Crocus sativus L* [32]	Saffron	Iridaceae	Petals
18.	*Emblica Officinalis*[33]	Amla	Euphorbiaceae	Fruit
19.	*Galphimia glauca* [34]	Rain of gold	Malpighiaceae	Whole plant
20.	*Gentiana kochiana* [35]	Trumpet gentian	Gentianaceae	Aerial parts
21.	*Gastrodia elata* [36]	Tian ma	Orchidaceae	Rhizome
22.	*Glycyrrhiza uralensis* [37]	Sweet root	Leguminaceae	Root
23.	*Glycyrrhiza glabra* [38]	Liquorice	Leguminaceae	Root
24.	*Hypericum perforatum* [39,40]	Goatweed	Hypericaceae	Aerial part
25.	*Hypericum reflexum* L. [41]	Hypericum	Hypericaceae	Aerial part
26.	*Kaempferia parviflora* [42]	Peacock ginger	Zingiberaceae	Whole plant
27.	*Lepidium meyenii* [43]	Maca	Brassicaceae	Hypocotyls
28.	*Marsilea minuta* Linn. [44]	Dwarf waterclover	Marsileaceae	Whole plant
29.	*Momordica charantia* [45]	Karela	Cucurbitaceae	Seed, root
30.	*Magnolia officinalis*[46]	Beaver tree	Magnoliaceae	Bark
31.	*Zingiber officinale* [46]	Ginger	Zingiberaceae	Rhizome
32.	*Morinda officinalis F.C* How [47,48]	Mulberry	Rubiaceae	Root
33.	*Mimosa pudica* Linn.[49]	Humble plant	Mimosaceae	Leaves
34.	*Nardostachys jatamansi* [50]	Nard	Balerianaceae	Root, rhizome
35.	*Ocotea duckei* [51]	Sweetweed	Lauraceae	Whole plant
36.	*Piper methysiticum* Forst [52]	Kava	Piperaceae	Root
37.	*Piper laetispicum* [53]	Xiao Chang-feng	Piperaceae	Stem, root
38.	*Paeonia lactiflora* [54]	Garden peony	Paeoniaceae	Root
39.	*Ptychopetalum olacoides* [55]	Marapama	Olacaceae	Bark, root
40.	*Rhazya stricta* [56]	Senhwar	Apocynaceae	Leaves
41.	*Radix puerariae* [57]	Kudzu root	Leguminaceae	Whole plant
42.	*Rosmarinus officinalis* [58]	Rosemary	Lamiaceae	Leaves
43.	*Siphocamphylus verticillatus* [59]	Mufumbo	Campanulaceae	Aerial part
44.	*Salvia elegans* [60]	Pineapple sage	Lamiaceae	Aerial parts
45.	*Schinus molle* L. [61]	Brazilian peppertree	Anacardiaceae	Leaves
46.	*Tinospora cordifolia* [62]	Giloe	Menispermaceae	Whole plant
47.	*Thymus pubescences* [63]	Firefly thyme	Lamiaceae	Root
48.	*Tabebuia avellanedae* [64]	Moreton bay chestnut	Bignoniaceae	Bark, leaves

ANTI-DEPRESSANT PLANTS:

The Indian landmass is enriched by a range of flora each aromatic and medicative plants. This is often due to the wide diversity of weather conditions in Asian country starting from deserts to swamplands. Varied kinds of herbs are well recognized and listed by life scientist from the high ranges of the chain tract up to the sea-shores of Kanyakumari. In recent years, specialize in plants analysis has inflated everywhere the globe and an oversized body of proof has been collected to indicate vast potential of medicative plants utilized in varied ancient systems.

The history of flavoring medicines is as recent as human civilization. The documents disclosed that plants were used medicinally in China, India, Egypt and Greece long before the start of the Christian era. The human being seems to be afflicted with a lot of diseases than the other animal's species.

They wanted to alleviate their sufferings from injury and illness by taking advantage of plant growing around them. Depression is such a standard disturbance that affects the personal and social relations of someone. There are style of neuro chemical theories proposed and range of artificial medication antidepressant are obtainable currently a days, but their effectiveness doesn't return up the whole vary of population tormented by this disorder. What are more the facet effects and also the drug interactions are major restrictions in their clinical applications. Unlike, artificial medications, seasoning medicines are wide used across the world because of their wide relevancy and therapeutic effectualness related to least facet effects that successively has initiated the research project concerning the medication activity. The aim of this review is to enlist those plants which have antidepressant activity and therefore the used to experimental models accustomed screen their numerous activity.

CONCLUSION:

A variety of chemical and artificial medication are obtainable to treat depression, however most of the patients fail to tolerate the adverse effects due to these medication. Moreover, 500 patients expertise a whole recovery. Currently, studies are being progressively conducted to observe new and economical medication to treat depression with no adverse effects. Meanwhile, medicinal plants are according to exert pharmacologically best effects in treating depression in numerous animal models (Herrera -Ruiz, Garccinal plants have been). Forced swim check and tail suspension check are animal pharmacological models normally accustomed investigate medication effects of chemical compounds and totally different plants in rodents (mostly mice). Additionally to the abovementioned plants, sure plants like apocynum venetum, common ginger Roscoe, Targets lucida Cav, eugenia brasiliensis Lam, Hedyosmum brasiliense, saffron crocus, Bupleurum Falcaria, scrophularia striata, rosid dicot genus notoginseng, and Piper methysticum are according to exert antidepressant effects.

In the lightweight of the above-mentioned, most of the healthful plants and their active compounds according during this critical review were found to exert therapeutic effects through interactions with serotonergic (5-5HT3, 5-5HT2A, and 5HT1A), noradrenergic receptors and dopaminergic (D1 and D2 receptors) systems. Additionally, healthful plants cause regulation of HPA axis activity and reduce within the magnified amounts of endocrine, CRH, endocrine and CRH. Aerophilic stress is one among the factors concerned in depression pathophysiology and totally different degrees of aerophilic stress and a decrease in anti-oxidant enzymes are according in individuals with depression. Proof indicates that the degrees of sure inflammatory mediators are higher in individuals with depression than others. Some healthful plants like Danggui-Shaoyao-San and E. brevicornum exert medication effects through reducing aerophilic stress and inflammatory mediators. A review of the findings on healthful plants' medication effects indicates that the majority analysis has been conducted on animal models and few plants together with H. perforatum and L. officinal is are investigated for medication effects in humans. Provided that the chemical compounds of the plants are metabolized through catalyst processes of the body and liver and for this reason their structure and actions are seemingly to vary, it's counseled to conduct clinical trials additionally to diagnosis studies. [17]

REFERENCE:

1. Iyer K. and Khan Z.A. Depression – A Review. International Science Congress Association. 2012; 1(4):79-87.
2. Bondy Brigitta. Pathophysiology of depression and mechanisms of treatment. Dialogues Clin Neurosci. 2002; 4(1):7-20.
3. Professor Ian Anderson. Depression The Treatment And Management Of Depression In Adults (Updated Edition). National Clinical Practice Guideline 90 National Collaborating Centre for Mental Health. Published by The British Psychological Society and The Royal College of Psychiatrists.
4. Gin S Malhi, J John Mann. Depression. The lancet. 2018; 392.
5. Jeffrey Greenberg, Anderson A. Tesfazion. Screening, Diagnosis, and Treatment of Depression Military Medicine. 2012; 177:8-60.
6. Wang J, Wu X, Lai W. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis.
7. Larry Culpepper, Philip R. Muskin, Stephen M. Stahl. Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability. The American Journal of Medicine, 2015; 9A, 128.
8. Parvaneh Isfahani , Marziye Arefy , and Monire Shamsaii. Prevalence of Severe Depression in Iranian Women with Breast Cancer: A Meta-Analysis. Hindawi Depression Research and Treatment. 2020:1-8.
9. Eman Dawood, Rufa Mitsu, Hind A, Ghadeer, Fatimah Alrabodh. Assessment of Depression and Its Contributing Factors among Undergraduate Nursing Students. International Journal of Nursing December 2017, Vol. 4, 2, pp. 69-79.
10. Adilson Marques, Miguel Peralta, Duarte Henriques-Neto, Diana Frasquilho, Elvio Rubio Gouveira and Diego Gomez-Baya. Active Commuting and Depression Symptoms in Adults: A Systematic Review. *International Journal of Environmental Research and Public Health*.
11. Jordan F. Karp, Mary Amanda Dew, Abdus S. Wahed, Kelley Fitzgerald, Chloe A. Bolon, Debra K. Weiner, Jennifer Q. Morse, Steve Albert, Meryl Butters, Ariel Gildengers, Charles F Reynolds III. Challenges and Solutions for Depression Prevention Research: Methodology for a Depression Prevention Trial for Older Adults with Knee Arthritis and Emotional Distress. The American Journal of Geriatric Psychiatry 2015; 10.012.
12. V.E. Pollock and L.S. Schneider. Quantitative, Waking EEG Research on Depression. Society of Biological Psychiatry. 1990; 27:757-780.

13. A Qahtani A and A Qahtani N. Prevention of Depression: A Review of Literature Journal of Depression and Anxiety. 2017; 6: 4.
14. Jamwal Neetu Singh, Kumar Sunil, Rana A.C. Antidepressant Activity of Methanolic Extract of Foeniculum Vulgare (Fennel) Fruits in Experimental Animal Models .Journal of Applied Pharmaceutical Science. 2013; 3 (09), pp. 065-070.
15. Rupesh K. Gautam, Praveen K. Dixit, Suchita Mittal. Herbal Sources of Antidepressant Potential: A Review, *International Journal of Pharmaceutical Sciences Review and Research*, 18(1), 2013, 86-91.
16. Dar A, Khatoon S, Behavioral and biochemical studies of dichloromethane fraction from the *Areca catechu* Nut., Pharmacol Biochem Behav,65 ,2000,1-6.
17. Butter V, Nisshibe S, Sasaki T, Uchida M, Antidepressant effects of *Apocynum venetum* leaves in the forced swimming test, Biol Pharm Bull., 24(7), 2001, 848-851
18. Kim JH, Kim SY, Lee SY, Jang CG. Antidepressant like effects of *Albizzia julibrissin* in mice: Involvement of the 5-HT1A receptor systems, Pharmacol Biochem Behav, 87, 2007, 41- 47.
19. Velraj M, Vijayalakshmi A, Jayakumari S, Ramamoorthy S, Ravichandiran V, Srikanth J, Antidepressant activity of the ethanolic extract of *Albizzia lebbeck* (Linn) bark in animal models of depression, Drug Invention Today , 1,2009, 112-115.
20. Sousa FCF, Melo CTV, Monteiro AP, Lima VTM, Gutierrez SJC, Pereira BA Antianxiety and antidepressant effects of riparin III from *Aniba riparia* (Nees) Me (Lauraceae) in mice,Pharmacol Biochem Behav, 78, 2004, 27-33.
21. Diaz-Veliz SMG, Millan R, Lungenstrass H, Quiros S, Coto-Morales T, Hellion- Ibarrola MC. Anxiolytic and antidepressant -like effects of the hydroalcoholic extract from *Aloysia polystachya* in rats. Pharmacol Biochem Behav 2005; 82:373-378.
22. Yoshino S, Kawai Y, Terao J, Antidepressant -like effect of onion (*Allium cepa* L.) powder in a rat behavioral model of depression, Biosci Biotechnol Biochem, 72, 2008, 94-100.
23. Singh GK, Garabadu D, Muruganandam AV, Joshi VK, Krishnamurthy S, Antidepressant activity of *Asparagus racemosus* in rodent models, Pharmacol Biochem Behav, 91, 2009, 283–290.
24. Sairam K, Dorababu M, Goel RK, Bhattacharya SK, Antidepressant activity of standardized extract of *Bacopa monniera* in experimental models of depression in rats, Phytomedicine, 9(3),2002, 207-211.
25. Pedersen ME, Szewczyk B, Stachowicz K, Wieronska J, Andersen J, Stafford GI. Effects of South African traditional medicine in animal models for depression. J Ethnopharmacol , 19,2008,542-548.
26. Kwon S, Lee B, Kim M, Lee H, Park HJ, Hahm DH, Antidepressant- like effect of the methanolic extract from *Bupleurum falcatum* in the tail suspension test, Prog Neuropsychopharmacol Biol Psych , 34,2009, 265-270.
27. Jain NN, Ohal CC, Shroff SK, Bhutada RH, Somani RS, Kasture VS, *Clitoria ternatea* and the CNS, Pharmacol Biochem Behav , 75,2003, 529-536.
28. Barauna SC, Kaster MP, Heckert BT, Nascimento KS, Rossi FM, Teixeira EH, Antidepressant like effect of lectin from *Canavalia brasiliensis* (ConBr) administered centrally in mice, Pharmacol Biochem Behav, 85, 2006, 60–169.
29. Yu ZF, Kong LD, Chen Y, Antidepressant activity of aqueous extracts of *Curcuma longa* in mice, J Ethnopharmacol, 83, 2002, 161-165.
30. Rocha FF, Lima-Landman MTR, Souccar C, Tanae MM, De Lima TCM, Lapa AJ, Antidepressant-like effect of *Cecropia glazioui* Sneth and its constituents – In vivo and in vitro characterization of the underlying mechanism, Phytomedicine,14,2007,396-402
31. Winterhoff H, Spengler B, Christoffel V, Butterweck V, Löhning A, Modern Phytotherapy in Menopause: *Cimicifuga racemosa* (Klimadynon, Menofem) Pharmacological and Clinical Data, 2002, Berlin. Cimicifuga extract BNO 1055: reduction of hot flushes and hints on antidepressant activity Maturitas. 44, 2003, S51-S58.
32. Hosseinzadeh H, Karimi G, Niapoor M. Antidepressant effect of *Crocus sativus* stigma extracts and their constituents, crocin and safranal, in mice, J Psychopharmacol,15,2001, 47- 54.
33. Kurkin VA, Dubishchev AV, Ezhkov VN, Titova IN, Avdeeva EV, Antidepressant activity of some phytopharma ceuticals and phenylpropanoids. Pharm Chem J,40, 2006, 614-619.
34. Herrera-Ruiz M, Jimenez-Ferrer JE, Lima TCM, Aviles-Montes D, Perez-Garcia D, Gonzalez-Cortazar M, Tortoriello J, Anxiolytic and antidepressant-like activity of a standardized extract from *Galphimia glauca*, Phytomedicine , 13,2006, 23-28.
35. Tomic M, Tovilovic G, Butorovic B, Krstic D, Jankovic T, Aljanic I, Neuropharmacological evaluation of diethylether extract and xanthones of *Gentiana kochiana*, Pharmacol Biochem Behav, 81, 2005, 535-542.
36. Zhou BH, Li XJ, Liu M, Wu Z, Hu XM, Antidepressant -like activity of the *Gastrodia elata* ethanol extract in mice, Fitoterapia, 77, 2006, 592-594.
37. Wang W, Hu X, Zhao Z, Liu P, Hu Y, Zhou J, Antidepressant-like effects of liquiritin and isoliquiritin from *Glycyrrhiza uralensis* in the forced swimming test and tail suspension test in mice, Prog Neuropsychopharmacol Biol Psych ,32,2008,1179–1184.
38. Ofir R, Tamir S, Khati S, Vaya J, Inhibition of serotonin re -uptake by liquorice constituents, J Mol Neurosci ,20, 2003, 135-140.
39. Nathan PJ. *Hypericum perforatum* (St John's Wort): a non-selective reuptake inhibitor- A review of the recent advances in its pharmacology, J Psychopharmacol, 15, 2001, 47–54.
40. Singer A, Wonnemann M, Muller WE, Hyperforin, a Major Antidepressant Constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular sodium, J Pharmacol Exp Ther, 290,1999, 1363-1368.
41. Sánchez-Mateo CC, Bonkanka CX, Prado B, Rabanal RM Antidepressant activity of some *Hypericum reflexum* L. fil. Extracts in the forced swimming test in mice. *Journal of Ethnopharmacology* 112(1), 2007, 115-121.
42. Wattanathorn J, Pangpookiew P, Muchimapura KSS, Sripanidkuchai B, Evaluation of the anxiolytic and antidepressant effects of alcoholic extract of *Kaempferia parviflora* in aged rats, African Journal of Animal and Biomedical Sciences, 2, 2007, 94-98.
43. Rubio J, Caldas M, Davila S, Gasco M, Gonzales GF, Effect of three different cultivars of *Lepidium meyenii* (Maca) on learning and depression in ovariectomized mice, Complement Altern Med 2006,6,23.
44. Bhattamisra SK, Khanna VK, Agrawal AK, Singh PN, Singh SK, Antidepressant activity of standardised extract of *Marsilea minuta* Linn. J Ethnopharmacol 117, 2008, 51–57.
45. Ganesan A, Natesan S, Perumal PG, Vellayutham R, Manickam K, Ramasamy N, Anxiolytic, Antidepressant and Anti -Inflammatory Activities of methanol extract of *Momordica charantia* Linn leaves, (Cucurbitaceae), Iranian Journal of Pharmacology & Therapeutics, 7, 2008, 43-47.
46. Yi LT, Xu Q, Li YC, Yang L, Kong LD, Antidepressant-like synergism of extracts from magnoliabark and ginger rhizome alone and in combination in mice, Prog Neuropsychopharmacol Biol Psych, 33, 2009, 616–624.
47. Zhang ZQ, Yuan I, Zhao N, Xu YK, Yang M, Luo ZP, Antidepressant effect of the ethanolic extracts of the roots of *Morinda officinalis* in rats and mice, Chin Pharm J, 35,2000, 739-741.
48. Zhang ZQ, Huang SJ, Yuan I, Zhao N, Xu YK, Yang M, Luo ZP, Zhao YM, Zhang YX, Effect of *Morinda officinalis* oligosaccharides on performance of the swimming test in mice and rats and the learned helplessness paradigm in rats,Chin J Pharmacol Toxicol. , 15, 2001, 262-265.
49. Molina M, Contreras CM, Tellez-Alcantara P, *Momosa pudica* may possess antidepressant actions in th e rat,Phytomedicine, 6(5),1999,319-323.
50. Dhingra D, Goyal PK, Inhibition of MAO and GABA: Probable mechanisms for antidepressant like activity in *Nardostachys jatamansi* DC. in mice. Indian J Exp Biol, 46, 2008, 212-218.
51. De Sousa FCF, Pereira BA, Lima VTM, Lacerda CDG , Melo CTV, Barbosa-Filho JM,Central nervous system activity of yangambin from *Ocotea duckei* Vattimo (Lauraceae) in mice, Phytother Res, 19, 2005, 282–286.
52. Uebelhack R, Franke L, Schewe HJ, Inhibition of MAO-B by kavapyrone-enriched extract from *Piper methysitcum* Foster(kava-kava), Pharmacopsychiatry, 31(5),1998, 187-192.
53. Yao CY, Wang J, Dong D, Qian FG, Xie J, Pan SL, Laetispicine, an amide alkaloid from *Piper laetispicum*, presents antidepressant and antinociceptive effects in mice, Phytomedicine ,16, 2009, 823- 829.
54. Mao Q, Huang Z, Ip S, Che C, Antidepressant -like effect of ethanol extract from *Paeonia lactiflora* in mice, Phytother Res ,22, 2008, 1496-1499.
55. Piato AL, Rizon LP, Martins BS, Nunes DS, Elisabetsky E, Antidepressant profile of *Ptychopetalum olacoides* Bentham (Marapuama) in mice, Phytother Res, 23, 2008,519-524.

56. Ali BH, Bashir AK, Tanira MO, Medvedev AE, Jarrett N, Sandler M, Effect of extract of *Rhazya stricta*, a traditional medicinal plant, on rat brain tribulin,Pharmacol Biochem Behav ,59,1998, 671-675.
57. Yan B, Wang DY, Xing DM, Ding Y, Wang RF, Lei F, The antidepressant effect of ethanol extract of *Radix puerariae* in mice exposed to cerebral ischemia reperfusion,Pharmacol Biochem Behav ,78,2004, 319-325.
58. Machado DG, Bettio LEB, Cunha MP, Capra JC, Dalmarco JB, Pizzolatti MG et al. Antidepressant -like effect of the extract of *Rosmarinus officinalis* in mice: Involvement of the monoaminergic system, Prog Neuropsychopharmacol Biol Psych, 33, 2009, 642- 650.
59. Rodrigues AL,da Silva GI,Masteussi AS,Fernandes ES,Miguel OG,Yunes RA,Calixto JB,Santos ARS, Involvement of monoaminergic system in the antidepressant like effect of the hydroalcoholic extract of *Siphocampylus verticillatus* , Life Sci, 70,2002,1347-1358.
60. Herrera-Ruiz M, Garcia-Beltran Y, Mora S, Diaz-Veliz G, Viana GSB, Tortoriella J,Antidepressant and anxiolyti c effects of hydroalcoholic extract from *Salvia elegans*, J Ethnopharmacol, 107, 2006, ,53-58.
61. Machado DG, Bettio LEB, Cunha MP, Santos ARS, Pizzolatti MG, Brighente IMS, Antidepressant -like effect of rutin isolated from the ethanolic extract from *Schinus molle* L. in mice: Evidence for the involvement of the serotonergic and noradrenergic systems, Eur J Pharmacol ,587,2008, 163-168.
62. Dhingra D, Goyal PK, Evidences for the involvement of monoaminergic and GABAergic systems in antidepressant -like activity of *Tinospora cordifolia* in mice,Indian J Pharm Sci ,70,2008, 761-765.
63. Morteza-Semnani K, Mahmoudi M, Riahi G, Effects of essential oils and extracts from certain Thymus Species on swimming performance in mice. Pharm Biol , 45, 2007, ,464-467.
64. Freitas AE, Budni J, Lobato KR, Binfare RW, Machado DG, Jacinto J, Antidepressant- like action of the ethanolic extract from *Tabebuia avellanedae* in mice: Evidence for the involvement of the monoaminergic system, Prog Neuropsychopharmacol Biol Psych, 34, 2010, 335-343.

ONLINE SOURCES:

1. https://www.whiteswanfoundation.org/disorders/mooddisorders/depression
2. https://www.state.nj.us/humanservices/dmhas/publications/miscl/MH_Fact_Sheets/NIMH_Depression.pdf